[The new basic agent prospidin in the therapy of rheumatoid arthritis. An evaluation of the clinical effectiveness and the mechanism of action of prospidin].
A therapeutic effect of prospidine, a Soviet antitumor drug, was studied on the basis of clinicoimmunological correlations in 74 patients with proved rheumatoid arthritis (RA) who were resistant to well known basic drugs. It was administered parenterally and intraarticularly according to the methods developed by the authors, and its effect on the indices of T- and B-immune response was studied. Prospidine was shown to possess a true and high (91.8%) antirheumatic activity producing an analgesic, antiexudative and antiproliferative effect; it was capable of lessening hormone dependence and causing remission bringing about no serious side-effects which could require discontinuation of therapy. At the same time the use of the drug resulted in an elevation of the level of T-suppressors, a decrease in the amount of B-cells, T-helpers, titers of the rheumatoid factor, antisynovial antibodies, cytopathic and lymphokine synthesizing activity. Its mechanism of action and indications for use were discussed. Prospidine was considered as a drug of choice in drug therapy of rheumatoid arthritis.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011447:Prospidium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D010879:Piperazines; D011447:Prospidium
Novoe bazisnoe sredstvo prospidin v terapii revmatoidnogo artrita. K otsenke klinicheskoĭ éffektivnosti i mekhanizma deĭstviia prospidina.